Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

Heider, Ulrike, Kaiser, Martin, Müller, Christian, Jakob, Christian, Zavrski, Ivana, Schulz, Carsten‐Oliver, Fleissner, Claudia, Hecht, Monica, Sezer, Orhan·2006·European Journal of Haematology

Abstract

Abstract: Objectives: Myeloma bone disease is a result of excessive osteoclast activation and impaired osteoblast function. Recent in vitro studies suggested that proteasome inhibitors might increase osteoblast function. Methods: We analyzed serum markers of osteoblast activity in 25 patients with multiple myeloma receiving bortezomib alone or in combination with dexamethasone. As control, serum samples from 58 consecutive myeloma patients receiving a therapy different than bortezomib (i.e. adriamycin/dexamethasone, melphalan/prednisone or thalidomide) were evaluated. The serum concentrations of bone‐specific alkaline phosphatase (BAP) and osteocalcin were quantified before initiation of treatment and after 3 months. Results: In patients treated with bortezomib, mean serum levels of osteocalcin significantly increased from 6.3 to 10.8 μ g/L (P = 0.024), while mean BAP levels increased from 19.7 to 30.2 U/L (P < 0.0005). Of interest, the increase in BAP was significant both in responders and non‐responders. In contrast, the control group did not show a statistically significant change in BAP (24.8 U/L vs. 23.3 U/L) and osteocalcin (6.8 μ g/L vs. 6.5 μ g/L) before and after the treatment. Conclusion: These data show that treatment with bortezomib leads to enhanced markers of osteoblast activity in patients with myeloma. The comparison with the control group suggests that the effect on osteoblasts is unique to the proteasome inhibitor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0609.2006.00692.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 161

Metadata

Authors
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O.
Venue
European Journal of Haematology
Publisher
Wiley
Published
2006-05-23
Volume
77
Issue
3
Pages
233-238
ISSN
  • 0902-4441 (ISSN-L)
  • 1600-0609
OpenAlex
W1973328408
Cited by
161
References
3
FWCI
9.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. https://app.cochat.ai/papers/10.1111/j.1600-0609.2006.00692.x
The paper
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O. (2006). Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2006.00692.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.